secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001213900-26-050951
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERo Therapeutics issues $500K convertible note to Keystone Capital at 10% interest
--------------------------------------------------------------------------------

- Initial purchase price $400,000; principal face value $500,000; up to $1M aggregate available.
- Note matures April 27, 2027; bears 10% annual interest; convertible at lower of $0.05 or 80% of 5 lowest intraday prices in prior 20 days.
- Conversion subject to 4.99% beneficial ownership limitation; resale registration required on Form S-1 or S-3.
- Issuance exempt under Section 4(a)(2) and Rule 506(b); accredited investor only.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/0001213900-26-050951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/ea028870101-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-050951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer